Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism

Thrombosis Journal

Table 5 Analysis of the association between the PAI-1 4G/5G polymorphism and VTE risk

Model	Cases	Controls	P value	OR	95% CI	Adjusted^a P value	Adjusted^a OR	Adjusted^a 95% CI
Allele
5G	72	52		1	-
4G	106	68	0.6206	1.126	0.704–1.800	0.545	1.201	0.664–2.171
Genotype
5G/5G	18	8		1	-
4G/5G	36	36	0.0872	0.444	0.172–1.152	0.8545	1.132	0.301–4.266
4G/4G	35	16	0.9569	0.972	0.350–2.700	0.7433	1.223	0.366–4.084
Dominant model
5G/5G	18	8		1	-
4G/5G + 4G/4G	71	52	0.2707	0.607	0.245–1.502	0.8645	1.105	0.351–3.480
Recessive model
4G/5G + 5G/5G	54	44		1	-
4G/4G	35	16	0.107	1.782	0.874–3.636	0.4414	1.415	0.585–3.424
Additive model
5G/5G	18	8	0.6215	1.125	0.705–1.797	0.5318	1.215	0.660–2.240
4G/5G	36	36
4G/4G	35	16

VTE Venous thromboembolism, HC Healthy control, RBC Red blood cell counts, Hb Hemoglobin, HCT Hematocrit, WBC White blood cell counts, L Lymphocyte counts, N Neutrophil counts, PLT Platelet counts, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, IQR Interquartile range, SD Standard deviation, OR Odds ratio CI Confidence interval, a Adjust for age and sex

ISSN: 1477-9560